We show that, compared with surgeon predictions and existing risk-prediction tools, our machine-learning model can enhance ...
Get the latest on Cellectar Biosciences' Q3 2025 earnings, EMA progress for iopofosine, clinical pipeline updates, and strategic outlook.
The options market for options on American Airlines ($AAL) stock has been turbulent as the airline presents a mixed picture ...
Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...
In the short run, when firms cannot reassign labor, change suppliers, or adjust technologies, output losses ripple through every downstream stage of production. A shortage of a single key input can ...
When can an artist using AI tools copyright their work? Early this year, the Copyright Office addressed this issue and ...
The latest round of country climate plans ‘barely move the needle’ on future warming, the head of the UN Environment ...
Econometrics, the application of statistical methods to economic data, can be instrumental in the identification of ...
Discover a practical blueprint for building a modern, intelligence-driven threat program aligned with enterprise risk and ...
Golf Monthly on MSN
Two-Time PGA Tour Winner Makes Disastrous Octuple Bogey 12 At World Wide Technology Championship
Luke List's third round unraveled spectacularly on his sixth hole of the day at Mexico's El Cardonal at Diamante ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback